Neurogene (NGNE) Common Equity (2013 - 2026)

Neurogene's Common Equity history runs 14 years deep, the most recent figure standing at $237.8 million for Q1 2026.

• Quarterly Common Equity fell 18.51% year-over-year to $237.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $237.8 million (down 18.51% YoY) and the FY2025 annual result came in at $264.9 million, down 14.66% from the prior year.
• Common Equity was $237.8 million for Q1 2026 at Neurogene, down from $264.9 million in the prior quarter.
• Across five years, Common Equity topped out at $310.4 million in Q4 2024 and bottomed at -$183.2 million in Q3 2023.
• A 5-year average of $117.0 million and a median of $155.0 million in 2024 frame the typical range for Common Equity.
• Peak annual rise in Common Equity reached 227.64% in 2023, while the deepest fall reached 273.42% in 2023.
• Neurogene's Common Equity stood at -$145.7 million in 2022, then surged by 227.64% to $186.0 million in 2023, then jumped by 66.85% to $310.4 million in 2024, then fell by 14.66% to $264.9 million in 2025, then decreased by 10.23% to $237.8 million in 2026.
• Business Quant data shows NGNE's Common Equity at $237.8 million in Q1 2026, $264.9 million in Q4 2025, and $265.5 million in Q3 2025.